Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose naloxone versus ondansetron for prevention of postoperative nausea and vomiting after sufentanil-based general anesthesia
IRCT20160307026950N52Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of naloxone and ondansetron in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Nausea and vomiting severity after surgery. Started Jun 2023; status: completed.
02
Drugs
naloxoneondansetron
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on IRCT20160307026950N52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160307026950N52.